Literature DB >> 5061836

Biochemical investigations in patients with Parkinson's disease treated with L-dopa.

E Jequier, J J Dufresne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5061836     DOI： 10.1212/wnl.22.1.15

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

Review 1.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

2.  Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine.

Authors:  J B Pilling; J Baker; L L Iversen; S D Iversen; T Robbins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-02       Impact factor: 10.154

Review 3.  Clinical pharmacokinetics of levodopa in parkinson's disease.

Authors:  J R Bianchine; G M Shaw
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

4.  The acetylcholine-dopamine balance in the basal ganglia of rhesus monkeys and its role in dynamic, dystonic, dyskinetic, and epileptoid motor activities.

Authors:  A R Cools; G Hendriks; J Korten
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

5.  Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease.

Authors:  W J Weiner; H L Klawans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-10       Impact factor: 10.154

6.  CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.

Authors:  D L Davidson; C M Yates; C Mawdsley; I A Pullar; H Wilson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-12       Impact factor: 10.154
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.